{
    "2020-09-23": [
        [
            {
                "time": "",
                "original_text": "CRO&CDMO投研体系之数据跟踪(系列四)：2020H1回顾与前瞻 疫情背景下中国企业竞争优势凸显",
                "features": {
                    "keywords": [
                        "CRO",
                        "CDMO",
                        "投研体系",
                        "数据跟踪",
                        "2020H1",
                        "疫情",
                        "竞争优势",
                        "中国企业"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业日报：估值步入合理区间 关注超跌个股",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业日报",
                        "估值",
                        "合理区间",
                        "超跌个股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}